Welcome to Drugs in Context

Drugs in Context is indexed in Clarivate JCR with a 2025 JIF of 2.8, is included in Clarivate ESCI, is a member of the Directory of Open Access Journals, and is listed on PubMed with all articles free-to-view/download immediately on PubMed Central

About

Drugs in Context publishes high-quality, peer-reviewed articles covering the latest evidence and innovations in pharmacotherapy and drug treatment across all therapeutic areas. We focus on original research papers and topical review articles; other article types are considered.

Journal metrics

Clarivate JCR 2024 JIF: 2.8; JCI: 0.45; Category Ranking: 157/352, Q2

 

Scopus CiteScore 2024: 5.0; SCImago Journal Rank 2024: 0.775; Source Normalized Impact per Paper: 0.962; Ranked 94 of 668 (86th percentile) in General Medicine journals and 140 of 321 (56th percentile) in Pharmacology journals

Article types

We publish original research papers and topical review articles. Other article types, including systematic reviews and meta-analyses, editorials, case reports, conference reports and Letters to the Editor, are also considered

Peer review

All manuscripts undergo single-blind external peer review with comments from at least two reviewers. A first editorial decision is aimed for within 4 weeks of submission and online publication within 4 weeks after acceptance

Submit your manuscript

Check the SUBMISSION page for full instructions. Submit your manuscript via Manuscript Manager.

Editorial Board

Drugs in Context is led by a team of Senior Editors supported by an extensive Editorial Board with expertise spanning all areas of modern medicine and pharmacotherapy.

Publishing Process & Peer Review

Drugs in Context is an Open Access journal, with articles freely accessible online for all readers. Articles are assessed for suitability upon submission or pre-submission and then sent for external peer review. There is no charge for submitting a manuscript for consideration.

Instructions for Authors

Publication in Drugs in Context is facilitated by our dedicated and responsive Editorial team. We offer simple and straightforward publication following best practices. For detailed submission guidelines, how to prepare your manuscript, timelines and charges, please read this section.

Latest Articles

Real-world effectiveness of a phlebotonic formulation combining diosmin, Ruscus, Melilotus and Vitis vinifera on symptoms and quality of life in patients with chronic venous and lymphatic disease: results from the VIVEMA Stasis observational study

Giampiero Avruscio, Carmen Tirritto, Sonia Ragazzo, Mario Mangrella, Roberto Piazza, Erica Tanasi

The VIVEMA Stasis observational study was designed to evaluate the symptom burden, oedema reduction and quality of life in patients with chronic venous disease, lymphoedema and/or phlebolymphatic oedema treated with a phlebotonic formulation containing diosmin, Ruscus aculeatus, Melilotus officinalis and Vitis vinifera, combined with functional bandaging and elastic compression therapy.

Read more
Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.

Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

 acquisto Viagra genericocomprar Cialis online en España